Navigation Links
DIA Conference to Focus on Clinical Trial Disclosure and the Importance of Transparency

HORSHAM, Pa (PRWEB) September 10, 2013

The DIA conference Clinical Trial Disclosure: Towards a More Transparent World will provide guidance on potential implications of the transparency of clinical trial information in registration, reporting and more. The meeting, to be held Oct. 1 to 2 in Bethesda, Md., will bring together academics, government regulators and patient advocates to provide key guidance on:

  •     Requirements for clinical trial disclosure in the United States and the European Union
  •     The interaction among medical writing, regulatory affairs and clinical trial disclosure to maintain consistency for protocol registration and the reporting of results
  •     The impact of greater transparency in clinical trial disclosure on industry and academia
  •     The advantages and implications of the availability of clinical trial disclosure databases

“The continuing proliferation of national and industry-sponsored registries leaves many sponsors considering disclosure strategy, developing operational measures and looking for efficient ways to manage dissemination of clinical trial protocol information. We are excited to bring together these leaders to discuss moving the needle in clinical trial disclosures,” said Susan Cantrell, director of DIA North America.

Speakers include:

  •     Jarilyn Dupont, director of regulatory policy, Food and Drug Administration
  •     Mark Barnes, partner, Ropes & Gray LLP
  •     Chris Galvin, analyst, Office of Inspector General, U.S. Department of Health and Human Services
  •     Jessica B. Gilbart, president and CEO, DC/MD/VA Chapter, Lupus Foundation of America
  •     Christine Laine, M.D., editor, Annals of Internal Medicine, and senior vice president, American College of Physicians
  •     Joseph Solomon Ross, M.D., assistant professor of medicine (general medicine) and of public health (health policy), Yale School of Medicine
  •     Michael Krumenacker, M.D., publication compliance officer, Sanofi

To find out more about the event and to register, visit DIA’s website for Clinical Trial Disclosure: Towards a More Transparent World.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Elsevier organizes label-free technologies conference
2. NJ stroke researchers report advances in spatial neglect research at AAN Conference
3. Blending conference translates substance abuse research into practice
4. International conference to explore health of descendants of transatlantic slave trade
5. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
6. Nobel laureate to keynote international pharmaceutical conference at URI
7. Pharmica Consulting to Hold HIT Conference for the Pharmaceutical Industry
8. Snoring Isn't Sexy Member Dr. Mark Levy attends Academy of Clinical Sleep Disorders Disciplines Conference in Phoenix, Arizona
9. AuntMinnie Begins Live Video Stream of ISCT Conference Proceedings
10. NOVAtime Solutions to be showcased at Booth #1821 in the upcoming Society for Human Resource Management (SHRM) Annual Conference and Exposition
11. International Nanomedicine Conference bound for Sydney: July 2-4, 2012
Post Your Comments:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology: